CTMX Logo

CytomX Therapeutics Inc (CTMX) Stock Forecast & Price Prediction

Live CTMX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$0.79

-0.05 (-5.95%)

12 Month Price Forecast For CTMX

$0.79
Current Price
$61.08M
Market Cap
7 Ratings
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings

Distance to CTMX Price Forecasts

+912.7%
To High Target of $8.00
+365.8%
To Median Target of $3.68
+311.4%
To Low Target of $3.25

CTMX Price Momentum

-16.0%
1 Week Change
-10.2%
1 Month Change
-48.4%
1 Year Change
-23.3%
Year-to-Date Change
-86.5%
From 52W High of $5.85
+1.3%
From 52W Low of $0.78

๐Ÿค” Considering CytomX (CTMX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 8:49 PM UTC

CTMX Analyst Ratings & Price Targets

Based on our analysis of 15 Wall Street analysts, CTMX has a bullish consensus with a median price target of $3.68 (ranging from $3.25 to $8.00). Currently trading at $0.79, the median forecast implies a 365.8% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Robert Driscoll at Wedbush, projecting a 912.7% upside. Conversely, the most conservative target is provided by Etzer Darout at BMO Capital, suggesting a 311.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CTMX Analyst Consensus

4
Buy
3
Hold
0
Sell

CTMX Price Target Range

Low
$3.25
Average
$3.68
High
$8.00
Current: $0.79

Latest CTMX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CTMX.

Date Firm Analyst Rating Change Price Target
Jan 7, 2025 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
Nov 11, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
Sep 13, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
Aug 22, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
Jun 27, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
May 28, 2024 Piper Sandler Joseph Catanzaro Overweight Upgrade $3.50
May 9, 2024 Wedbush Robert Driscoll Outperform Upgrade $8.00
May 9, 2024 BMO Capital Etzer Darout Market Perform Maintains $3.59
May 9, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $0.00
May 6, 2024 Jefferies Roger Song Buy Upgrade $8.00
May 1, 2024 BMO Capital Etzer Darout Market Perform Reiterates $3.25
Apr 22, 2024 JP Morgan Anupam Rama Neutral Upgrade $0.00
Mar 12, 2024 BMO Capital Etzer Darout Market Perform Maintains $3.25
Mar 12, 2024 Wedbush Robert Driscoll Neutral Reiterates $3.00
Nov 9, 2023 Wedbush Robert Driscoll Neutral Maintains $3.00
Nov 8, 2023 Wedbush Robert Driscoll Outperform Upgrade $3.00
Aug 9, 2023 BMO Capital Etzer Darout Market Perform Maintains $3.19
Mar 28, 2023 Mizuho Mara Goldstein Neutral Maintains $2.00
Jan 6, 2023 BMO Capital Etzer Darout Market Perform Maintains $3.20
Nov 14, 2022 BMO Capital Etzer Darout Market Perform Downgrade $2.60

Stocks Similar to CytomX Therapeutics Inc

The following stocks are similar to CytomX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

CytomX Therapeutics Inc (CTMX) Financial Data

CytomX Therapeutics Inc has a market capitalization of $61.08M with a P/E ratio of 4.9x. The company generates $126.62M in trailing twelve-month revenue with a 10.9% profit margin.

Revenue growth is +26.7% quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of +1.2%.

Valuation Metrics

Market Cap $61.08M
Enterprise Value $-41,253,540
P/E Ratio 4.9x
PEG Ratio -1.3x
Price/Sales 0.5x

Growth & Margins

Revenue Growth (YoY) +26.7%
Gross Margin N/A
Operating Margin +12.3%
Net Margin +10.9%
EPS Growth +91.7%

Financial Health

Cash/Price Ratio +190.3%
Current Ratio 1.0x
Debt/Equity -0.5x
ROE +1.2%
ROA +2.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

CytomX Therapeutics Inc logo

CytomX Therapeutics Inc (CTMX) Company Overview

About CytomX Therapeutics Inc

What They Do

Develops innovative biologics for cancer treatment.

Business Model

The company leverages its proprietary conditional activation platform technology to develop targeted oncology therapeutics. It generates revenue through partnerships and collaborations with major pharmaceutical companies, as well as through the advancement of its product pipeline, which includes bispecific antibodies and antibody-drug conjugates aimed at improving treatment efficacy and safety for cancer patients.

Additional Information

CytomX Therapeutics has a robust development pipeline focusing on various cancer types and has established strategic collaborations with industry leaders such as Amgen and Bristol Myers Squibb. The company is well-positioned in the oncology sector, utilizing its innovative technologies to enhance the therapeutic index of existing treatments while pursuing new therapeutic modalities.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

120

CEO

Dr. Sean A. McCarthy DPHIL

Country

United States

IPO Year

2015

CytomX Therapeutics Inc (CTMX) Latest News & Analysis

CTMX stock latest news image
Quick Summary

CX-2051, a wholly-owned EpCAM PROBODYยฎ ADC program, is progressing well, with initial Phase 1a clinical data in advanced metastatic colorectal cancer expected in H1 2025.

Why It Matters

The positive progress on CX-2051 suggests potential for significant breakthroughs in cancer treatment, influencing market sentiment and stock valuations for biotech investors.

Source: GlobeNewsWire
Market Sentiment: Neutral
CTMX stock latest news image
Quick Summary

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.

Why It Matters

CytomX Therapeutics' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and stock price.

Source: Zacks Investment Research
Market Sentiment: Positive
CTMX stock latest news image
Quick Summary

CytomX Therapeutics (CTMX) shows signs of recovery with a hammer chart pattern and revised higher earnings estimates from Wall Street analysts, indicating potential for a near-term turnaround.

Why It Matters

CytomX Therapeutics shows potential for recovery with technical support and analyst upgrades, signaling possible future stock price appreciation.

Source: Zacks Investment Research
Market Sentiment: Positive
CTMX stock latest news image
Quick Summary

CytomX Therapeutics CEO Sean McCarthy will speak at the Piper Sandler Healthcare Conference on December 4, 2024, at 8:00 a.m. ET.

Why It Matters

CytomX Therapeutics' CEO participation in a major healthcare conference can signal potential insights on company performance and strategic direction, influencing investor sentiment and stock price.

Source: GlobeNewsWire
Market Sentiment: Neutral
CTMX stock latest news image
Quick Summary

CytomX Therapeutics (CTMX) is in oversold territory, indicating potential for a trend reversal, supported by analysts raising earnings estimates.

Why It Matters

CytomX Therapeutics may see a rebound due to oversold conditions and increased earnings estimates from analysts, signaling potential upward momentum for investors.

Source: Zacks Investment Research
Market Sentiment: Positive
CTMX stock latest news image
Quick Summary

CytomX Therapeutics, Inc. (NASDAQ:CTMX) will hold its Q3 2024 earnings conference call on November 7, 2024, at 5:00 PM ET, featuring key executives and analysts from major firms.

Why It Matters

The Q3 earnings call will provide insights into CytomX's financial performance and strategic direction, influencing stock valuation and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Neutral

Frequently Asked Questions About CTMX Stock

What is CytomX Therapeutics Inc's (CTMX) stock forecast for 2025?

Based on our analysis of 15 Wall Street analysts, CytomX Therapeutics Inc (CTMX) has a median price target of $3.68. The highest price target is $8.00 and the lowest is $3.25.

Is CTMX stock a good investment in 2025?

According to current analyst ratings, CTMX has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.79. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CTMX stock?

Wall Street analysts predict CTMX stock could reach $3.68 in the next 12 months. This represents a 365.8% increase from the current price of $0.79. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is CytomX Therapeutics Inc's business model?

The company leverages its proprietary conditional activation platform technology to develop targeted oncology therapeutics. It generates revenue through partnerships and collaborations with major pharmaceutical companies, as well as through the advancement of its product pipeline, which includes bispecific antibodies and antibody-drug conjugates aimed at improving treatment efficacy and safety for cancer patients.

What is the highest forecasted price for CTMX CytomX Therapeutics Inc?

The highest price target for CTMX is $8.00 from Robert Driscoll at Wedbush, which represents a 912.7% increase from the current price of $0.79.

What is the lowest forecasted price for CTMX CytomX Therapeutics Inc?

The lowest price target for CTMX is $3.25 from Etzer Darout at BMO Capital, which represents a 311.4% increase from the current price of $0.79.

What is the overall CTMX consensus from analysts for CytomX Therapeutics Inc?

The overall analyst consensus for CTMX is bullish. Out of 15 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $3.68.

How accurate are CTMX stock price projections?

Stock price projections, including those for CytomX Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.